Point-of-care CD4 testing: Differentiated care for the most vulnerable

Background South Africa, with the highest burden of HIV infection globally, has made huge strides in its HIV/ART programme, but AIDS deaths have not decreased proportionally to ART uptake. Advanced HIV disease (CD4<200 cells/mm(3)) persists, and CD4 count testing is being overlooked since universal test-and-treat was implemented. Point-of-care CD4 testing could address this gap and assure differentiated care to these vulnerable patients with low CD4 counts. Methods A time randomised implementation trial was conducted, enrolling 603 HIV positive non-ART, not pregnant patients at a primary health care clinic in Durban, South Africa. Weeks were randomised to either point-of-care CD4 testing (n=305 patients) or standard-of-care central laboratory CD4 testing (n=298 patients) to assess the proportion initiating ART at 3 months. Cox regression, with robust standard errors adjusting for clustering by week, were used to assess the relationship between treatment initiation and arm. Results Among the 578 (299 point-of-care and 279 standard-of-care) patients eligible for analysis, there was no significant difference in the number of eligible patients initiating ART within 3 months in the point-of-care (73%) and the standardof-care (68%) groups (P=0.112). The time-to-treat analysis was not significantly different in patients with CD4 counts of 201-500 cells/rnm(3) which could have been due to appointment scheduling to cope with the large burden of cases. However, in patients with advanced HIV disease (CD4<200cells/mm(3)) 65% more patients started ART earlier in the point-of-care group (HR 1.65 (95% confidence interval (CI)=0.99-2.75; P=0.052) compared to the standard-of-care group. Conclusions Point-of-care testing decreased time-to-treatment in those with advanced HIV disease. With universal test and treat for HIV, rollout of simple pointof-care CD4 testing would ensure early diagnosis of advanced HIV disease and facilitate differentiated care for these vulnerable patients as per the World Health Organisation 2020 target product profile for point-of-care CD4 testing.